Enhance neural stem cell chemoxis toward CNS inflammatory foci in EAE
增强 EAE 中神经干细胞对 CNS 炎症灶的趋化作用
基本信息
- 批准号:7871136
- 负责人:
- 金额:$ 7.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAnimal ModelAutologousBone MarrowBrainCellsChemotaxisChronicClinicalDemyelinationsEmbryoEncephalomyelitisEngineeringEthicsExperimental Autoimmune EncephalomyelitisHarvestHumanImmunotherapyInfiltrationInflammationInflammatoryInjection of therapeutic agentMultiple SclerosisMusMyelinNatureNeuraxisNeuronsPatientsPropertyRecoveryRecovery of FunctionRelapseRelative (related person)ReportingSiteStagingTestingTherapeuticTherapeutic EffectTransplantationcellular engineeringchemokinechemokine receptoreffective therapymigrationnerve stem cellnovelpublic health relevancereceptorreceptor expressionsubventricular zone
项目摘要
DESCRIPTION (provided by applicant): Neural stem cells (NSCs) have been shown to be effective in suppressing experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Among the studies, two exciting reports by the same group (Pluchino et al., Nature, 2003 and 2005) showed that both systemic and local injection of NSCs from the subventicular zone (SVZ) of adult mice promotes multifocal remyelination and functional recovery in EAE. However, this approach has obvious drawbacks, with a relatively slow and limited clinical benefit. Lack or low expression of particular chemokine receptors on NSCs could be an important factor underlying these weaknesses. Further, due to the relative inaccessibility of SVZ-NSCs, harvesting these cells is highly invasive. Thus, bone marrow (BM)- derived NSCs may be the best alternative in a clinical setting. Given the high levels of different chemokines at the inflammatory foci of various stages/types of MS/EAE, we hypothesize that BM-NSCs engineered to express selected chemokine receptors will guide NSCs to migrate more efficiently and rapidly to inflammatory sites, inhibit local inflammation to a certain extent and promote remyelination, thus more effectively suppressing EAE. To test this hypothesis, we will augment BM-NSC chemotaxis towards inflammatory sites by expressing selected chemokine receptors on these NSCs. We believe that this approach will endow BM-NSCs with rapid and guided migration to EAE foci, thus accelerating the intrinsic capacity of NSCs to promote remyelination and neuronal recovery, and blocking further myelin/neuron damage. This approach may lay the groundwork for a novel, easily accessible and highly effective approach to MS therapy.
PUBLIC HEALTH RELEVANCE: A more rapid and more effective suppression of MS may be achieved by genetically engineering neural stem cells to express a receptor corresponding to the elevated level of chemokines in inflammatory foci. From an ethical standpoint, the use of neural stem cells derived from bone marrow is high desirable. Our study could lay the groundwork for a novel, more rapid and more effective therapy for MS patients.
描述(由申请人提供):神经干细胞(NSC)已被证明可有效抑制实验性自身免疫性脑脊髓炎(EAE),一种多发性硬化症(MS)的动物模型。在这些研究中,同一小组的两份令人兴奋的报告(Pluchino等人,Nature,2003和2005)显示,全身和局部注射来自成年小鼠脑室下区(SVZ)的NSC促进EAE中的多灶性髓鞘再生和功能恢复。然而,这种方法具有明显的缺点,具有相对缓慢且有限的临床益处。神经干细胞上特定趋化因子受体的缺乏或低表达可能是导致这些弱点的重要因素。此外,由于SVZ-NSC的相对不可及性,收获这些细胞是高度侵入性的。因此,骨髓(BM)来源的神经干细胞可能是临床环境中的最佳选择。鉴于不同阶段/类型的MS/EAE的炎性病灶处不同趋化因子的高水平,我们假设经工程化以表达选定趋化因子受体的BM-NSC将引导NSC更有效和快速地迁移到炎性部位,在一定程度上抑制局部炎症并促进髓鞘再生,从而更有效地抑制EAE。为了验证这一假设,我们将通过在这些NSC上表达选定的趋化因子受体来增强BM-NSC对炎症部位的趋化性。我们相信,这种方法将赋予BM-NSC快速和引导迁移到EAE病灶,从而加速NSC促进髓鞘再生和神经元恢复的内在能力,并阻断进一步的髓鞘/神经元损伤。这种方法可能为MS治疗的一种新的、容易获得的和高效的方法奠定基础。
公共卫生相关性:通过遗传工程改造神经干细胞以表达对应于炎性病灶中升高水平的趋化因子的受体,可以实现对MS的更快速和更有效的抑制。从伦理学的角度来看,使用来自骨髓的神经干细胞是非常可取的。我们的研究可以为MS患者的新的,更快速,更有效的治疗奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GUANG-XIAN ZHANG其他文献
GUANG-XIAN ZHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GUANG-XIAN ZHANG', 18)}}的其他基金
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair
熊果酸:一种通过免疫调节和神经修复治疗慢性 MS/EAE 的新型口服疗法
- 批准号:
9923753 - 财政年份:2017
- 资助金额:
$ 7.73万 - 项目类别:
Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair
熊果酸:一种通过免疫调节和神经修复治疗慢性 MS/EAE 的新型口服疗法
- 批准号:
9384085 - 财政年份:2017
- 资助金额:
$ 7.73万 - 项目类别:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
NSC 在 CNS 中产生三重有效的鸡尾酒,用于 MS/EAE 治疗
- 批准号:
8849995 - 财政年份:2012
- 资助金额:
$ 7.73万 - 项目类别:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
NSC 在 CNS 中产生三重有效的鸡尾酒,用于 MS/EAE 治疗
- 批准号:
8545912 - 财政年份:2012
- 资助金额:
$ 7.73万 - 项目类别:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
NSC 在 CNS 中产生三重有效的鸡尾酒,用于 MS/EAE 治疗
- 批准号:
8439993 - 财政年份:2012
- 资助金额:
$ 7.73万 - 项目类别:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
NSC 在 CNS 中产生三重有效的鸡尾酒,用于 MS/EAE 治疗
- 批准号:
8661315 - 财政年份:2012
- 资助金额:
$ 7.73万 - 项目类别:
NSCs produce a triply effective cocktail in the CNS for MS/EAE therapy
NSC 在 CNS 中产生三重有效的鸡尾酒,用于 MS/EAE 治疗
- 批准号:
9120428 - 财政年份:2012
- 资助金额:
$ 7.73万 - 项目类别:
Enhance neural stem cell chemoxis toward CNS inflammatory foci in EAE
增强 EAE 中神经干细胞对 CNS 炎症灶的趋化作用
- 批准号:
8021789 - 财政年份:2010
- 资助金额:
$ 7.73万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 7.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists